Katie Planey, PhD, MBA, joined Acelot as a member of the Board of Directors in 2021 and as Chief Executive Officer in 2022. Katie has extensive experience in the field of biotechnology and business strategy, with a special ability to define key strategic initiatives in uncharted and complex scientific and engineering fields. They are a driven and perceptive entrepreneur passionate about creating data-savvy biotech companies from the ground up. Drawing from their extensive expertise in technical strategy, engineering, and biomedical informatics, they are dedicated to advancing science for the benefit of patients and public health.

Prior to their work at Acelot, Katie co-Founded Mantra Bio, an exosome therapeutics company, and led its research efforts and indications strategy as CTO for six years. Katie received an MBA and a PhD in Biomedical Informatics from Stanford University and a B.S. in Biomedical Engineering from Yale University.